Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 191

The DOI matches its Crossref record.

Benign Prostatic Hyperplasia

Langan, Robert C.·2019·Primary Care: Clinics in Office Practice
DOI 10.1016/j.pop.2019.02.003
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pop.2019.02.003

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 43

  1. McVary, 2006, BPH: epidemiology and comorbidities, Am J Manag Care, 12, S122
  2. Kapoor, 2012, Benign prostatic hyperplasia (BPH) management in the primary care setting, Can J Urol, 19, 10
  3. Jones, 2010, Management of lower urinary tract symptoms in men: summary of the NICE guidelines, BMJ, 340, c2354, 10.1136/bmj.c2354 · DOI
  4. Sarma, 2012, Benign prostatic hyperplasia and lower urinary tract symptoms, N Engl J Med, 367, 248, 10.1056/NEJMcp1106637 · DOI · Paper page
  5. Bartsch, 2000, Dihydrotestosterone and the concept of 5-alpha-reductase inhibition in human benign prostatic hyperplasia, Eur Urol, 37, 367, 10.1159/000020181 · DOI
  6. Simon, 2016, Does prostate size predict the development of incident lower urinary tract symptoms in men with mild to no current symptoms? Results from the REDUCE trial, Eur Urol, 69, 885, 10.1016/j.eururo.2015.12.002 · DOI
  7. Schwinn, 2008, α1-Adrenoceptor subtypes and lower urinary tract symptoms, Int J Urol, 15, 193, 10.1111/j.1442-2042.2007.01956.x · DOI
  8. Andersson, 2004, Antimuscarinics for the treatment of overactive bladder, Lancet Neurol, 3, 46, 10.1016/S1474-4422(03)00622-7 · DOI · Paper page
  9. Andersson, 2011, Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action, Neurourol Urodyn, 30, 292, 10.1002/nau.20999 · DOI
  10. Kristal, 2007, Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial, J Urol, 177, 1395
  11. Giovannucci, 1994, Obesity and benign prostatic hyperplasia, Am J Epidemiol, 140, 989, 10.1093/oxfordjournals.aje.a117206 · DOI
  12. Sarma, 2012, Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men, Urology, 79, 102, 10.1016/j.urology.2011.08.065 · DOI
  13. Parsons, 2009, Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia, J Urol, 182, 1463
  14. Platz, 1998, Physical activity and benign prostatic hyperplasia, Arch Intern Med, 158, 2349, 10.1001/archinte.158.21.2349 · DOI
  15. Barry, 1992, The American Urological Association symptom index for benign prostatic hyperplasia, J Urol, 148, 1549
  16. Barry, 1995, Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?, J Urol, 154, 1770
  17. Wadie, 2001, The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction. Part I: when statistics fail, J Urol, 165, 32
  18. Wuerstle, 2011, Contribution of common medications to lower urinary tract symptoms in men, Arch Intern Med, 171, 1680, 10.1001/archinternmed.2011.475 · DOI
  19. Vuichoud, 2015, Benign prostatic hyperplasia: epidemiology, economics, and evaluation, Can J Urol, 22, 1
  20. McVary, 2011, Update on AUA guideline on the management of benign prostatic hyperplasia, J Urol, 185, 1793
  21. Bohnen, 2007, Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study, Eur Urol, 51, 1645, 10.1016/j.eururo.2007.01.084 · DOI
  22. McNeill, 2001, Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin, Urology, 57, 459, 10.1016/S0090-4295(00)01021-9 · DOI
  23. McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 · DOI
  24. ALLHAT Officers, 2000, Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), JAMA, 283, 1967, 10.1001/jama.283.15.1967 · DOI · Paper page
  25. Djavan, 1999, A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction, Eur Urol, 36, 1, 10.1159/000019919 · DOI
  26. Jung, 2017, Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia, Cochrane Database Syst Rev
  27. Chrischilles, 2001, Initiation of nonselective alpha 1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study, Clin Ther, 23, 727, 10.1016/S0149-2918(01)80022-9 · DOI
  28. Welk, 2015, The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study, BMJ, 351, h5398, 10.1136/bmj.h5398 · DOI
  29. Guillaume, 2007, Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects, J Clin Pharmacol, 47, 1303, 10.1177/0091270007306559 · DOI
  30. Chang, 2005, Intraoperative floppy iris syndrome associated with tamsulosin, J Cataract Refract Surg, 31, 664, 10.1016/j.jcrs.2005.02.027 · DOI
  31. Bell, 2009, Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery, JAMA, 301, 1991, 10.1001/jama.2009.683 · DOI
  32. Roehrborn, 2011, Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), Med Clin North Am, 95, 87, 10.1016/j.mcna.2010.08.013 · DOI
  33. McConnell, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, N Engl J Med, 338, 557, 10.1056/NEJM199802263380901 · DOI · Paper page
  34. Nickel, 2011, Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS), BJU Int, 108, 388, 10.1111/j.1464-410X.2011.10195.x · DOI
  35. Thompson, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, 215, 10.1056/NEJMoa030660 · DOI
  36. Thompson, 2013, Long-term survival of participants in the prostate cancer prevention trial, N Engl J Med, 369, 603, 10.1056/NEJMoa1215932 · DOI · Paper page
  37. Walsh, 2010, Chemoprevention of prostate cancer, N Engl J Med, 362, 1237, 10.1056/NEJMe1001045 · DOI
  38. Roehrborn, 2010, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign hyperplasia: 4-year results from the CombAT study, Eur Urol, 57, 123, 10.1016/j.eururo.2009.09.035 · DOI · Paper page
  39. McVary, 2007, Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia, J Urol, 177, 1401
  40. Tacklind, 2012, Serenoa repens for benign prostatic hyperplasia, Cochrane Database Syst Rev
  41. Roehrborn, 2013, The prostatic urethral life for treatment of urinary tract symptoms associated with prostate enlargement due to BPH: the LIFT Study, J Urol, 190, 2161
  42. Roehrborn, 2017, Five year results of the prospective randomized controlled prostatic urethral LIFT study, Can J Urol, 24, 8802
  43. Sonksen, 2015, Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study, Eur Urol, 68, 643, 10.1016/j.eururo.2015.04.024 · DOI

Cited by

See all 191

Metadata

Authors
Langan, R. C.
Venue
Primary Care: Clinics in Office Practice
Publisher
Elsevier BV
Published
2019-06
Volume
46
Issue
2
Pages
223-232
ISSN
0095-4543
DOI
10.1016/j.pop.2019.02.003
Cited by
191
References
0
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benign Prostatic Hyperplasia. https://app.cochat.ai/papers/10.1016/j.pop.2019.02.003
The paper
Langan, R. C. (2019). Benign Prostatic Hyperplasia. Primary Care: Clinics in Office Practice. https://doi.org/10.1016/j.pop.2019.02.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.